<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03293940</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00094527</org_study_id>
    <nct_id>NCT03293940</nct_id>
  </id_info>
  <brief_title>Cryoablation for Post Mastectomy Pain Syndrome</brief_title>
  <official_title>Percutaneous Image Guided Cryoablation of the Intercostobrachial Nerve for Management of Post Mastectomy Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, parallel-group, treatment control trial with cross-over
      options performed at four sites. The purpose of this study is to assess the efficacy and
      safety of cryoablation therapy for the treatment of post mastectomy pain syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, parallel-group, treatment control trial with cross-over
      options performed at four sites. The purpose of this study is to assess the efficacy and
      safety of cryoablation therapy for the treatment of post mastectomy pain syndrome.

      Participants will be randomized to receive cryoablation or a therapeutic peripheral nerve
      block injection (tPNB). All participants will be evaluated at baseline and after treatment at
      10 days, 90 days, and 180 days via clinical visits.

      The option to undergo cryoablation or tPNB will be offered to all participants at the end of
      the 90 day post-procedure assessment. Each subject that elects the crossover intervention
      will be assessed over the same time period and in an identical fashion to the initial
      intervention, including a final long term follow up (LTFU) assessment at 180 days
      post-cryoablation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Anticipated">July 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Breast Pain Intensity assessed by the Visual Analog Scale (VAS) Score</measure>
    <time_frame>Baseline, Post-Intervention (24 Hours)</time_frame>
    <description>Participants' ratings of perceived pain intensity will be captured with the VAS, a 10cm horizontal line with the extremes labeled, &quot;No pain&quot; and &quot;Worst Possible Pain. Participants mark a point along the continuum and it is scored by measuring the distance, in mm, from the &quot;no pain&quot; end to the participant's mark. A greater the distance from the &quot;no pain&quot; mark to the participants mark indicates greater pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Numerical Rating Scale (NRS) of Pain Intensity Score</measure>
    <time_frame>Baseline, Post-Intervention (24 Hours)</time_frame>
    <description>The NRS is an 11-point rating scale with 0 = &quot;No Pain&quot; and 10 = &quot;Pain as bad as you can imagine&quot;. Total scores range from 0-10 points, with higher scores indicating greater pain intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change Scale (PGIC) Score</measure>
    <time_frame>Post-Intervention (Up to 24 Hours)</time_frame>
    <description>The PGIC is a comprehensive, single-item estimate of treatment-related improvement that asks participants to consider their current status compared to pre-treatment and rate it on a 7-point scale (very much improved, much improved, minimally improved, no change, minimally worse, much worse, very much worse). Total scores range from 1 to 7; 1 representing no change and 7 representing considerable improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory Short Form (BPI) Score</measure>
    <time_frame>Post-Intervention (Up to 24 Hours)</time_frame>
    <description>The BPI captures two broad pain domains: 1) the sensory intensity of pain, and 2) the degree to which pain interferes with different areas of life. Scores are based on the two domains: the pain severity score is the mean of items 3-6 (pain at its worst, pain at its least). The pain interference score is the mean of items 9A-9G (interference of pain with: general activity, mood, walking, normal work, relations, sleep,enjoyment of life). Higher pain scores indicate greater pain and greater interference with daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>McGill Pain Questionnaire Short Form 2 (MPQ) Score</measure>
    <time_frame>Post-Intervention (Up to 24 Hours)</time_frame>
    <description>The MPQ consists of 24 assessments: 22 questions list a qualitative description of pain symptoms that patients may have felt during the past week and 1 question evaluates present pain intensity, both of which are rated on a numerical rating scale with 0= &quot;None&quot; and 10= &quot;Worst Possible&quot;; the final question evaluates the patient's overall total pain experience on a 6-item scale (no pain, mild, discomforting, distressing, horrible, excruciating). Total scores are on a continuum. The higher the total score, the pain experience for the participant increases.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lost to Follow Up Rate</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of participants who cannot be contacted prior to completing all study visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Death Rate</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of deaths that occur throughout the duration of the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant Withdrawal Rate</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of participants who withdraw from the study prior to completing all visits and after providing consent for participation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Declination Rate</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of eligible participants who decline study participation after being approached to participate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Screen Failure Rate</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of participants who are not eligible for study participation after conducting screening procedures.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Post Mastectomy Participants Enrolled</measure>
    <time_frame>Post Study Completion (Up to 2 Years)</time_frame>
    <description>Of the total number of post mastectomy patients at all sites, the percentage of patients who have consented to study participation.</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant Retention Rate</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of participants who sign consent and complete all study visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Total Recruitment Number</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The total number of participants recruited to the study.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of Breakthrough Pain Events</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The frequency of breakthrough pain events that require emergency or rescue analgesic use measured in hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Breakthrough Pain Events</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of breakthrough pain events that require emergency or rescue analgesic use reported during study visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Participants that Experience Adverse Events</measure>
    <time_frame>Duration of Study (Up to 180 Days)</time_frame>
    <description>The number of participants who experience adverse events divided by the total number of participants.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Post-Mastectomy Chronic Pain Syndrome (Disorder)</condition>
  <arm_group>
    <arm_group_label>Cryoablation Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the cryoablation procedure.
Participants will have the option to crossover to tPNB 90 days post the initial intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After an initial diagnostic visit to locate the pain causing nerve, participants randomized to this arm will receive the nerve block procedure.
Participants will have the option to crossover to cryoablation treatment 90 days post the initial intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.</description>
    <arm_group_label>Cryoablation Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Peripheral Nerve Block (tPNB) Injection</intervention_name>
    <description>During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.
The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Status post breast surgical intervention, to include mastectomy, partial mastectomy,
             lumpectomy, or reconstruction

          -  Persistent pain in the distribution of the Intercostobrachial nerve: the residual
             breast, surgical bed, ipsilateral medial arm, and/or axilla following tissue healing
             (&gt; 1 month postoperative)

          -  Positive response to local anesthetic nerve block, performed under imaging guidance. A
             positive response is defined as a â‰¥ 3 point change on a standard 11 point visual
             analog scale (VAS)

          -  Ability and willingness to provide informed consent

        Exclusion Criteria:

          -  Active infection

          -  Underlying cervical segmentation or other cervical spinal anomaly that results in
             differential nerve root pressures

          -  Immunosuppression

          -  Uncorrectable coagulopathy

          -  Currently pregnant, nursing or planning to become pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Prologo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Rivas</last_name>
    <phone>404-712-7962</phone>
    <email>mrivas2@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rivas</last_name>
      <phone>404-712-7962</phone>
      <email>mrivas2@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rivas</last_name>
      <phone>404-712-7962</phone>
      <email>mrivas2@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory St. Joseph's Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rivas</last_name>
      <phone>404-712-7962</phone>
      <email>mrivas2@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Johns Creek Hospital</name>
      <address>
        <city>Johns Creek</city>
        <state>Georgia</state>
        <zip>30097</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rivas</last_name>
      <phone>404-712-7962</phone>
      <email>mrivas2@emory.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>September 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2017</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>John Prologo</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Pain</keyword>
  <keyword>Nerve Pain</keyword>
  <keyword>Mastectomy</keyword>
  <keyword>Lumpectomy</keyword>
  <keyword>Breast Reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

